ConductScience.org, home

Comparison · NCT06042855-385bbda3

Arm G - Metformin vs Arm G - Placebo: Number of Participants With Mortality

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm G - Metformin vs Arm G - Placebo: Number of Participants With Mortality. Trial comparisons, record NCT06042855-385bbda3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06042855-385bbda3

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 100.0000000000000000002170.00266wilson
Risk in group 2000.00248wilson
Risk difference, group 1 minus group 20-0.002480.00266newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm G - Metformin
Metformin IR tablets will be self-administered orally according to the following dosing schedule:~* 500 mg on Day 1;~* 500 mg in the morning and 500 mg in the evening on Day 2 through Day 5; and~* 500 mg in the morning and 2 x 500 mg (a total of 1000 mg) in the evening on Day 6 through Day 14.~Metformin: Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
01,443OG000
Group 2Arm G - Placebo
Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing.~Placebo: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
01,548OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Mortality
Description
Time frame
Up to 28 days
Population

Source ClinicalTrials.gov

Trial

Title
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
NCT number
NCT06042855
Phases
PHASE3
Conditions
Covid19
Interventions
Placebo, Metformin
Lead sponsor
Susanna Naggie, MD
Results first posted
2025-07-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT06042855-385bbda3